<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02587364</url>
  </required_header>
  <id_info>
    <org_study_id>1027-003</org_study_id>
    <nct_id>NCT02587364</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics and Pharmacodynamics Study of Gemcabene in Healthy Volunteers</brief_title>
  <official_title>An Oral, Rising, Multiple‐Dose Tolerance, Pharmacokinetic and Pharmacodynamic Study of Gemcabene Capsules in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gemphire Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gemphire Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the multiple‐dose pharmacokinetic characteristics
      and pharmacologic activity of gemcabene.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 1999</start_date>
  <completion_date type="Actual">September 1999</completion_date>
  <primary_completion_date type="Actual">September 1999</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics</measure>
    <time_frame>29 days</time_frame>
    <description>Cmax</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetcis</measure>
    <time_frame>29 days</time_frame>
    <description>Area Under the Curve (AUC)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma lipid levels - percent change from baseline at Day 29</measure>
    <time_frame>29 days</time_frame>
    <description>percent change from baseline for LDL-C, apolipoprotein B (apoB), total cholesterol (TC), triglyceride (TG), very low density lipoprotein (VLDL-C), high density lipoprotein (HDL-C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>29 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ECG</measure>
    <time_frame>29 days</time_frame>
    <description>Clinically Significant Changes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Laboratory - hematology, chemistry</measure>
    <time_frame>29 days</time_frame>
    <description>Clinical Laboratory Abnormalities</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Gemcabene 50 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 150 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 150 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 450 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 450 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 750/600 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 750/600 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcabene 900 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemcabene 900 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcabene 50 mg</intervention_name>
    <description>Gemcabene 50 mg once daily (QD)</description>
    <arm_group_label>Gemcabene 50 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcabene 150 mg</intervention_name>
    <description>Gemcabene 150 mg once daily (QD)</description>
    <arm_group_label>Gemcabene 150 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcabene 450 mg</intervention_name>
    <description>Gemcabene 450 mg once daily (QD)</description>
    <arm_group_label>Gemcabene 450 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcabene 750/600 mg</intervention_name>
    <description>Gemcabene 750/600 mg once daily (QD)</description>
    <arm_group_label>Gemcabene 750/600 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcabene 900 mg</intervention_name>
    <description>Gemcabene 900 mg once daily (QD)</description>
    <arm_group_label>Gemcabene 900 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo once daily (QD)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Good health as determined by medical history, physical examination, electrocardiogram
             (ECG), vital signs, and laboratory assessments

          -  Body weight: 60‐100 kg (desirable)

        Exclusion Criteria:

          -  Use of any medication not considered acceptable by the clinical investigators during
             the 14‐day period before the start of the study (Day 1) ;

          -  Donation of a unit of blood or participation in a study of investigational or marketed
             drugs during the 30‐day period before the start of the study (Day 1);

          -  If female, of childbearing potential or lactating;

          -  History of significant reaction to any fibrate lipid‐lowering agent; and

          -  Significant urine collection of any drug which could interfere with the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>October 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2015</study_first_submitted>
  <study_first_submitted_qc>October 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 27, 2015</study_first_posted>
  <last_update_submitted>October 23, 2015</last_update_submitted>
  <last_update_submitted_qc>October 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Lipid Regulator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

